🔍

INSECTICID - Insecticid.India

📊 NSE: INSECTICID 🏢 Pesticides / Agrochemicals - Indian 📅 Last Updated: 12/14/2025 8:08

📢 Recent Corporate Announcements

Insecticides (India) to Attend Bharat Connect Investor Conference on March 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Mar 2026, 01:08 PM

Insecticides (India) Limited has announced its participation in the 'Bharat Connect Conference: Rising Stars' scheduled for March 10, 2026. The engagement will be a virtual group meeting starting at 3:00 PM with various institutional investors and analysts. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during the session. This is a routine disclosure as per SEBI Listing Obligations and Disclosure Requirements.

Scheduled to participate in Bharat Connect Conference: Rising Stars on March 10, 2026
The meeting is organized as a virtual group interaction starting at 3:00 PM
Aims to engage with institutional investors and analysts regarding company performance
Management confirms that no unpublished price sensitive information will be disclosed
The schedule is subject to change based on exigencies from either the company or investors

💡 Investors should monitor the stock exchange for any post-conference presentations or transcripts that may provide updated management commentary on industry trends. No immediate trading action is required based on this routine scheduling announcement.

Insecticides (India) Reports 8% Q3 Revenue Growth; 9M PAT Stands at ₹128 Crores

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 04 Feb 2026, 02:38 PM

Insecticides (India) Limited (IIL) delivered a resilient performance in Q3 FY26 with 8% revenue growth, driven by volume expansion and B2B segment strength despite a challenging market. For the 9M FY26 period, revenue reached ₹1,714 crores, up 4% year-on-year, while PAT remained flattish at ₹128 crores due to increased finance and depreciation costs. The company is aggressively pursuing premiumization, with premium products now contributing 59% of the B2C portfolio. Management expects Q4 to remain under margin pressure but maintains a medium-term sustainable growth target of 8-10%.

9M FY26 revenue increased to ₹1,714 crores from ₹1,641 crores, a growth of 4% YoY.
Gross profit for the 9-month period improved by 7% to ₹546 crores, though Q4 margins are expected to face pressure.
Premium products now account for 59% of the B2C segment, reflecting a strategic shift away from generics.
Launched 5 new products in 9M FY26, including SPARCLE and Altair, with 5 more planned for the upcoming Kharif season.
New manufacturing capacities at Dahej and Sotanala are on track to be operational by the end of FY26 and next Kharif respectively.

💡 Investors should focus on the company's transition toward high-margin premium products and the timely commissioning of the Dahej plant. While near-term margin headwinds persist, the growing share of 'Maharatna' brands and new global collaborations provide a positive medium-term outlook.

Insecticides (India) Releases Q3 & 9M FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 30 Jan 2026, 07:40 PM

Insecticides (India) Limited has officially released the audio recording of its earnings conference call for the third quarter and nine months ended December 31, 2025. The call, held on January 30, 2026, provided management's perspective on the company's financial performance and operational updates. This disclosure follows the announcement of the Unaudited Standalone and Consolidated Financial Results. Investors can access the recording on the company's website to understand the underlying drivers of the recent quarterly performance.

Audio recording of Q3 & 9M FY 2025-26 earnings call made available on January 30, 2026.
The call followed the release of Unaudited Standalone and Consolidated Financial Results.
Compliance maintained under Regulation 30 and 46 of SEBI (LODR) Regulations, 2015.
Direct access link provided for investor transparency and record.

💡 Investors should listen to the recording to identify management's guidance on product launches and margin sustainability for the final quarter of FY26.

Insecticides (India) Releases Q3 & 9M FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 30 Jan 2026, 03:20 PM

Insecticides (India) Limited has officially released the audio recording of its earnings conference call for the third quarter and nine months ended December 31, 2025. The call, conducted on January 30, 2026, involved discussions regarding the company's standalone and consolidated financial performance. This disclosure follows the requirements of SEBI Listing Obligations and Disclosure Requirements. The recording provides a platform for investors to hear management's detailed commentary on the company's operational trajectory and market conditions.

Audio recording of Q3 & 9M FY 2025-26 earnings call made available on the company website.
The call was held on January 30, 2026, following the release of financial results for the period ending December 31, 2025.
Compliance with SEBI Regulation 30 and 46 for transparent investor communication.
Management discussed both standalone and consolidated financial performance during the session.

💡 Investors should listen to the recording to gain insights into management's outlook on the agrochemical industry and specific growth drivers for the upcoming quarters. Particular attention should be paid to any guidance provided regarding raw material costs and new product pipelines.

Insecticides (India) Q3 Revenue Up 8% to ₹385 Cr; PAT Drops 40% on Margin Pressure

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 30 Jan 2026, 03:15 PM

Insecticides (India) Limited reported a mixed Q3 FY26, with revenue growing 8% YoY to ₹385 crore, driven primarily by the B2B segment. However, Profit After Tax (PAT) saw a sharp decline of 40% YoY to ₹10 crore, impacted by higher finance costs, depreciation, and a shift in product mix. For the nine-month period (9M FY26), revenue grew 4% to ₹1,714 crore, while PAT remained flat at ₹128 crore. Management attributed the margin compression to industry-wide headwinds and erratic rainfall affecting the high-margin B2C segment.

Q3 Revenue from operations increased by 8% YoY to ₹385 crore.
Profit After Tax (PAT) for Q3 fell significantly by 40% YoY to ₹10 crore.
EBITDA margins contracted to 7.1% in Q3 FY26 from 8.6% in the previous year.
Gross profit margins moderated to 32.4% due to a higher B2B sales mix and industry pressures.
Launched 5 new products during 9M FY26, including Sparcle and Torry Super, to drive future growth.

💡 Investors should be cautious due to the significant decline in quarterly profitability and margin contraction. Monitor the company's ability to pass on costs and shift the mix back toward high-margin B2C products in upcoming quarters.

Insecticides (India) Declares ₹2 Interim Dividend; Q3 Consolidated PAT Drops 39% YoY

🟡 NEUTRAL ⭐ 7/10

DIVIDEND 📅 30 Jan 2026, 02:50 PM

Insecticides (India) Limited has declared an interim dividend of ₹2 per share (20% of face value) for FY 2025-26, with the record date set for February 6, 2026. While consolidated revenue for Q3 FY26 grew by 7.6% YoY to ₹38,491.62 Lacs, the consolidated net profit saw a sharp decline of 39.2% to ₹1,053.82 Lacs. The bottom line was primarily pressured by a significant spike in finance costs, which rose from ₹140.61 Lacs to ₹468.18 Lacs YoY. Additionally, the company confirmed the successful dissolution of its Dubai-based subsidiary, IIL Overseas DMCC.

Declared an interim dividend of ₹2.00 per equity share (20% of FV ₹10) with a record date of Feb 6, 2026.
Consolidated Revenue from Operations increased 7.6% YoY to ₹38,491.62 Lacs in Q3 FY26.
Consolidated Net Profit fell 39.2% YoY to ₹1,053.82 Lacs compared to ₹1,733.30 Lacs in the previous year.
Finance costs surged by 233% YoY to ₹468.18 Lacs, impacting overall profitability.
Basic and Diluted EPS for the quarter dropped to ₹3.60 from ₹5.96 in the year-ago period.

💡 While the dividend provides a small immediate return, investors should be cautious of the sharp decline in net profit and rising interest expenses. Monitor the company's margin recovery and debt levels in the coming quarters before increasing exposure.

Insecticides (India) Reports Nil Requests for Physical Share Transfer Re-lodgement

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 28 Jan 2026, 03:36 PM

Insecticides (India) Limited has submitted a compliance report regarding the re-lodgement of transfer requests for physical shares as per SEBI guidelines. The report, issued by the Registrar and Share Transfer Agent (RTA) Alankit Assignments Limited, covers the period from January 1, 2026, to January 6, 2026. During this specific window, the company received zero requests for the transfer of physical shares. This filing is a routine procedural update following the SEBI circular dated July 2, 2025.

Zero (NIL) requests received for re-lodgement of physical share transfers during the reporting period.
Compliance update submitted pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97.
Report covers the status as of January 6, 2026, as confirmed by RTA Alankit Assignments Limited.
No requests were processed, approved, or rejected during the specified timeframe.

💡 This is a routine regulatory disclosure with no impact on company fundamentals or financial performance; no action is required from investors.

Insecticides (India) Promoters Transfer 67.65% Stake to Family Trusts for Succession Planning

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 27 Jan 2026, 11:24 AM

The promoter group of Insecticides (India) Limited has completed an internal reorganization, transferring 1,96,83,052 equity shares, representing 67.65% of the company's share capital, to four family trusts. This transfer was executed as a gift at nil value for the purpose of succession planning and streamlining family assets. The transaction was conducted following a specific exemption granted by SEBI in December 2025, ensuring no open offer was triggered. Since this is an internal reshuffle within the promoter group, the total promoter shareholding remains unchanged.

Transfer of 1,96,83,052 equity shares (67.65% stake) to family-controlled trusts.
Sanskriti Family Trust emerged as the largest holder among the trusts with a 64.66% stake.
Transaction executed as an off-market gift with zero monetary consideration.
Exemption granted by SEBI under Regulation 11(5) of SAST Regulations to facilitate the transfer.
Move is aimed at long-term succession planning and internal reorganization of promoter assets.

💡 This is a routine internal restructuring for succession planning and does not change the company's fundamentals or management control. Investors should treat this as a neutral event.

Insecticides (India) to Host Q3 & 9M FY26 Earnings Call on January 30, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 17 Jan 2026, 04:52 PM

Insecticides (India) Limited has scheduled its earnings conference call for Friday, January 30, 2026, at 5:00 PM IST. The call is intended to discuss the company's financial performance for the third quarter and nine months ended December 31, 2025. Senior management, including the Managing Director and CFO, will be present to address investor queries. The financial results are slated for release on the same day, providing a comprehensive view of the company's recent operational health.

Earnings conference call scheduled for January 30, 2026, at 05:00 PM IST
Discussion will focus on Q3 and 9M FY26 financial results ending December 31, 2025
Management participants include MD Rajesh Kumar Aggarwal and CFO Sandeep Kumar Aggarwal
Financial results to be officially announced on the same day as the call
Dial-in numbers provided for India, Hong Kong, Singapore, USA, and UK

💡 Investors should track the financial results on January 30 for updates on revenue growth and margin performance. The conference call will be crucial for understanding management's outlook on the upcoming Kharif season and raw material pricing.

Insecticides (India) Board to Meet Jan 30 for Q3 Results and Interim Dividend; Record Date Feb 6

🟢 POSITIVE ⭐ 7/10

BOARD_MEETING 📅 14 Jan 2026, 03:42 PM

Insecticides (India) Limited has scheduled a board meeting on January 30, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board will also consider the declaration of an interim dividend for the financial year 2025-26. If a dividend is declared, the company has pre-emptively fixed February 6, 2026, as the record date for determining shareholder eligibility. Additionally, the trading window for insiders has been closed since January 1, 2026, and will remain so until 48 hours after the results are announced.

Board meeting scheduled for January 30, 2026, to consider Q3 and 9M FY26 financial results.
Proposal for an interim dividend for FY 2025-26 to be discussed during the meeting.
Record date for the potential interim dividend is fixed as February 6, 2026.
Trading window for insiders remains closed from January 1, 2026, until 48 hours post-result declaration.

💡 Investors should watch for the Q3 earnings performance and the quantum of the interim dividend on January 30. Those looking to qualify for the dividend should ensure they hold the stock before the February 6 record date.

Insecticides (India) Board to Meet Jan 30 for Q3 Results and Interim Dividend

🟢 POSITIVE ⭐ 7/10

BOARD_MEETING 📅 14 Jan 2026, 03:41 PM

Insecticides (India) Limited has scheduled a board meeting on January 30, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. In addition to the earnings report, the board will consider the declaration of an interim dividend for the financial year 2025-26. If a dividend is declared, the company has already fixed February 6, 2026, as the record date for determining shareholder eligibility. The trading window for insiders has been closed since January 1, 2026, and will remain so until 48 hours after the results are announced.

Board meeting scheduled for January 30, 2026, to discuss Q3 and 9M FY26 results.
Proposal for interim dividend for FY 2026 to be considered during the same meeting.
Record date for the potential interim dividend is set for February 6, 2026.
Trading window for insiders remains closed from January 1, 2026, until 48 hours post-announcement.

💡 Investors should track the Q3 earnings performance and the dividend payout ratio on January 30 to assess the company's cash flow health. Those interested in the dividend must ensure they hold shares before the ex-dividend date preceding February 6.

Insecticides (India) Submits SEBI Regulation 74(5) Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 04:13 PM

Insecticides (India) Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by Alankit Assignments Limited, confirms the processing of dematerialization requests for the quarter ended December 31, 2025. This is a standard administrative filing required by all listed companies to ensure the integrity of shareholding records. There is no impact on the company's financial performance or business operations.

Compliance certificate submitted for the quarter ended December 31, 2025
Issued by Registrar and Share Transfer Agent, Alankit Assignments Limited
Confirms adherence to SEBI (Depositories and Participants) Regulations, 2018
Standard regulatory filing with no material impact on business operations

💡 No action is required from investors as this is a routine regulatory compliance filing. Focus should remain on the company's upcoming quarterly financial results.

Insecticides (India) Reports Zero Physical Share Transfer Requests for December 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Jan 2026, 12:46 PM

Insecticides (India) Limited has filed a status report regarding the re-lodgement of transfer requests for physical shares as of December 31, 2025. This filing is in compliance with a SEBI circular from July 2025 which established a special window for such transactions. The company's Registrar and Share Transfer Agent, Alankit Assignments Limited, reported that zero requests were received or processed during the month. This is a standard regulatory disclosure and has no impact on the company's financial health or business operations.

Compliance report filed as per SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97.
Zero requests for re-lodgement of physical share transfers were received during December 2025.
Zero requests were processed, approved, or rejected by the Registrar during the period.
The report confirms the status of the special window for physical share transfers as of December 31, 2025.

💡 No action is required from the majority of shareholders. Investors still holding physical share certificates should consult the company's Registrar to understand dematerialization requirements.

Insecticides (India) Promoters to Transfer 67.65% Stake to Family Trusts for Succession Planning

🟡 NEUTRAL ⭐ 7/10

REGULATORY 📅 29 Dec 2025, 07:34 PM

The promoter group of Insecticides (India) Limited is executing an internal reorganization to transfer a total of 67.65% stake to four family trusts. SEBI has granted a specific exemption from open offer requirements as the transaction is a non-commercial gift intended for succession planning. The Sanskriti Family Trust will emerge as the primary holding entity with a 64.66% stake. Total promoter group holding will remain unchanged at 72.30% following the completion of these transfers on or after January 05, 2026.

Transfer of 1,96,83,052 shares representing 67.65% of the company's share capital to four family trusts.
Sanskriti Family Trust to acquire the largest portion of 1,88,14,302 shares (64.66% stake).
Transaction is conducted as a gift without monetary consideration for internal family reorganization.
SEBI granted exemption from Regulation 3(1) and 4 of SAST Regulations via order dated December 02, 2025.
Total promoter and promoter group shareholding remains constant at 72.30%.

💡 This is a structural internal reorganization for succession planning and does not impact the company's fundamentals or operations. Investors should treat this as a neutral administrative event with no change in overall promoter control.

Insecticides (India) to Close Trading Window from Jan 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Dec 2025, 12:30 PM

Insecticides (India) Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is ahead of the upcoming board meeting to approve the financial results for the quarter ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are declared. The specific date for the board meeting will be communicated separately in due course.

Trading window closure effective from January 01, 2026.
Closure pertains to the review of financial results for the quarter ending December 31, 2025.
Trading restriction applies to all Designated Persons and their immediate relatives.
Window will reopen 48 hours after the official declaration of the Q3 results.
Board meeting date for result approval to be announced at a later date.

💡 This is a standard regulatory procedure and does not impact the company's fundamentals. Investors should monitor for the announcement of the board meeting date to track the upcoming Q3 performance.

View All INSECTICID Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Revenue from operations grew 2% YoY in Q2 FY26 to INR 638 Cr from INR 627 Cr. For FY25, revenue reached INR 2,000 Cr, a 2% increase from INR 1,966 Cr in FY24, driven by a 10% CAGR in brand formulations and institutional sales over the last three fiscals.

Geographic Revenue Split

The company maintains a pan-India presence with a network of over 7,500 distributors. While specific regional percentage splits are not disclosed, the company is actively expanding into new geographies to diversify its domestic market footprint.

Profitability Margins

Gross profit for Q2 FY26 increased 11% YoY to INR 220 Cr (34.5% margin) from INR 199 Cr. Consolidated PAT for FY25 was INR 142.02 Cr, up 39% from INR 102.08 Cr in FY24, reflecting a shift toward high-margin premium products.

EBITDA Margin

EBITDA margin improved to 13% in H1 FY26, up from the historical range of 10-11%. This 200-300 bps improvement is attributed to the 'premiumization' strategy and increased sales of innovative Maharatna molecules.

Capital Expenditure

The company has no major debt-funded capex proposed over the medium term. Historical capex has been managed through internal accruals, maintaining a healthy financial risk profile with a gearing ratio below 0.1 time as of March 31, 2025.

Credit Rating & Borrowing

CRISIL upgraded the long-term rating to 'CRISIL A+/Stable' from 'CRISIL A' in July 2025. Interest coverage ratio is estimated at 13-14 times for FY25, supported by steady profitability and low debt levels.

⚙️ Operational Drivers

Raw Materials

Technicals and basic chemical intermediates represent the primary raw material costs. The company is moving toward n-4 and n-5 stages of manufacturing to reduce dependency on imported intermediates.

Import Sources

Not specifically disclosed in the documents, though the company mentions moving to basic stages of manufacturing to mitigate market competition and supply chain volatility.

Capacity Expansion

Current capacity includes over 140 formulations of insecticides, herbicides, and fungicides. While specific MTPA figures are not provided, the company plans to build inventory from INR 600 Cr to INR 800 Cr to support the upcoming manufacturing season starting January.

Raw Material Costs

Raw material costs are highly sensitive to commodity price volatility; a sharp price fluctuation in Q4 FY23 led to a 9% operating loss. The company uses backward integration (n-1 to n-5 stages) to protect margins against these fluctuations.

Manufacturing Efficiency

Efficiency is driven by innovation and farmer training. The company is focusing on 'Focus Maharatna' products which offer higher margins (35-40% average, some exceeding 50%) compared to generic formulations.

Logistics & Distribution

Distribution is handled through a network of 7,500+ dealers. The company is focusing on the B2C segment to improve realizations and market penetration.

📈 Strategic Growth

Expected Growth Rate

8-10%

Growth Strategy

Growth will be achieved through 'premiumization' of the product portfolio, specifically targeting double-digit growth in Maharatna products. The company is also expanding its R&D efforts for patented molecules and leveraging its JV with OAT & IIL India Laboratories for new product development.

Products & Services

Agrochemical formulations including insecticides, herbicides, fungicides, and household pesticides.

Brand Portfolio

Maharatna, Focus Maharatna, and recently acquired brands intended to aid the business risk profile.

New Products/Services

The company is continuously launching new innovative molecules; patented molecules are expected to contribute significantly to margins, with some products yielding over 50% margin.

Market Expansion

Expansion is targeted through deeper penetration in the domestic B2C market and increasing the contribution of recently acquired brands to the overall revenue mix.

Market Share & Ranking

The company holds an established market position in the domestic agrochemicals industry, though specific percentage ranking is not disclosed.

Strategic Alliances

Joint Venture: OAT & IIL India Laboratories Private Limited, focused on R&D and new molecule discovery.

🌍 External Factors

Industry Trends

The industry is shifting from generic formulations to specialized, innovative molecules. IIL is positioning itself by increasing its EBITDA margin trajectory to 13% through R&D-led product launches.

Competitive Landscape

Competes with domestic and multinational crop care companies. While peers reported revenue declines in Q2 FY26, IIL achieved 2% growth due to its diversified product mix.

Competitive Moat

Moat is built on a strong brand (Maharatna), a massive distribution network of 7,500+ dealers, and R&D capabilities through JVs. These are sustainable due to the high entry barriers in discovery-led agrochemicals.

Macro Economic Sensitivity

Highly sensitive to agricultural GDP and monsoon performance. A 20-day dry spell followed by heavy rains in Q2 FY26 impacted the normal agronomic cycle.

Consumer Behavior

Farmers are increasingly seeking high-yield protection, leading to a shift toward premium 'Focus Maharatna' products over traditional generics.

Geopolitical Risks

Susceptible to global commodity price shifts and government policies regarding pesticide usage and environmental norms.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to government policies on agriculture, pesticide registration requirements, and environmental manufacturing standards for chemical plants.

Taxation Policy Impact

Tax expense for FY25 was INR 50.75 Cr on a consolidated profit before tax of INR 192.77 Cr, representing an effective tax rate of approximately 26.3%.

⚠️ Risk Analysis

Key Uncertainties

Monsoon variability remains the primary risk, with potential to impact sales by disrupting application windows. Inventory price risk is also significant, as seen in the 9% operating loss in Q4 FY23.

Geographic Concentration Risk

Primarily focused on the Indian domestic market; however, the 7,500+ dealer network provides wide internal geographic diversification.

Third Party Dependencies

Dependency on technical grade manufacturers is being mitigated through backward integration to n-4 and n-5 stages.

Technology Obsolescence Risk

Legacy products face competitive intensity and potential regulatory bans; the company mitigates this by investing in a pipeline of innovative and patented molecules.